Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.
about
Cerebrovascular disease in ageing and Alzheimer's diseaseNovel targeted therapeutics for metastatic castration-resistant prostate cancer.Anti-endothelin drugs in solid tumors.Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancerRole of the endothelin axis and its antagonists in the treatment of cancerThe endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?New molecular targets in advanced prostate cancer.Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.Endothelin receptor antagonists in cancer therapy.Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers.Emerging drugs for prostate cancer.Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials.Zibotentan for the treatment of castrate-resistant prostate cancer.Novel options for the treatment of castration-resistant prostate cancer.Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletionTherapeutic potential of endothelin receptor antagonism in kidney disease.Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs.Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
P2860
Q26771852-E5EEC907-FA13-4152-8F82-70546E79821BQ33642278-63BB5EE6-655E-4268-B9BD-DB32883AD045Q34021011-806790E5-BA2A-43AA-9459-CFC9D07FDBB3Q34161050-DC2B61CB-E429-48D5-B4A1-A82E7A8AD22AQ34433349-3AE7AE23-C5E4-4ED8-BA90-5324DD435D1AQ34919570-DF90A359-A673-43D5-9840-C90718F5CC4CQ36510011-F26B86BB-BFC3-4787-91CE-6DA9942E5AC2Q36532080-AE603DD4-3256-4BE1-8F7D-043438381A7BQ36857782-70C0BD9A-CEEE-45FC-B611-AD9208A0D650Q37024077-DCBAEA76-2C00-4EC2-B1D8-B68DFAF970B0Q37256842-EF5738AB-E6A2-43C2-AD74-648FDB22F20AQ37570555-A3263A66-FEE1-447F-9461-BFCA80107048Q37573815-CB8E67BA-E28D-4CF9-99E4-53FB8287A518Q37760222-EC28EC6A-EB0E-47CA-8A6A-242A2D5C2762Q37958741-EFB99B43-F64B-4B1A-96AB-B7EECE242222Q38108308-A93F6313-9280-4DBB-83FD-267418C219DCQ38678678-92F545CA-2B7A-4105-89F7-7E26DDBBA01BQ39680529-812008C0-70DC-4E14-82EA-FBA68D32468BQ40285992-C75DB6AD-1A32-4B68-BA72-948F1D7501E6Q42829416-6E96BF83-5C51-477F-89D7-AC2AABCD137AQ48663991-5461F0B9-35B3-4A59-9D7D-2E66147A500AQ51452538-1DF2874C-240C-47D5-8419-27E3B13906A4Q53401668-EB43DC7E-E220-4D34-9F62-A0176C60633B
P2860
Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Specific inhibition of the end ...... cal and pre-clinical evidence.
@ast
Specific inhibition of the end ...... cal and pre-clinical evidence.
@en
type
label
Specific inhibition of the end ...... cal and pre-clinical evidence.
@ast
Specific inhibition of the end ...... cal and pre-clinical evidence.
@en
prefLabel
Specific inhibition of the end ...... cal and pre-clinical evidence.
@ast
Specific inhibition of the end ...... cal and pre-clinical evidence.
@en
P2093
P2860
P356
P1476
Specific inhibition of the end ...... ical and pre-clinical evidence
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602676
P407
P577
2005-06-01T00:00:00Z